Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/197296
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cortellini, Alessio | - |
dc.contributor.author | Dettorre, Gino M. | - |
dc.contributor.author | Dafni, Urania | - |
dc.contributor.author | Aguilar Company, Juan | - |
dc.contributor.author | Castelo Branco, Luis | - |
dc.contributor.author | Lambertini, Matteo | - |
dc.contributor.author | Gennatas, Spyridon | - |
dc.contributor.author | Angelis, Vasileios | - |
dc.contributor.author | Sita-Lumsden, Ailsa | - |
dc.contributor.author | Rogado, Jacobo | - |
dc.contributor.author | Pedrazzoli, Paolo | - |
dc.contributor.author | Viñal, David | - |
dc.contributor.author | Prat Aparicio, Aleix | - |
dc.contributor.author | Rossi, Maura | - |
dc.contributor.author | Berardi, Rossana | - |
dc.contributor.author | Alonso Gordoa, Teresa | - |
dc.contributor.author | Grisanti, Salvatore | - |
dc.contributor.author | Dimopoulou, Georgia | - |
dc.contributor.author | Queirolo, Paola | - |
dc.contributor.author | Pradervand, Sylvain | - |
dc.contributor.author | Bertuzzi, Alexia | - |
dc.contributor.author | Bower, Mark | - |
dc.contributor.author | Arnold, Dirk | - |
dc.contributor.author | Salazar Soler, Ramón | - |
dc.contributor.author | Tucci, Marco | - |
dc.contributor.author | Harrington, Kevin J. | - |
dc.contributor.author | Mazzoni, Francesca | - |
dc.contributor.author | Mukherjee, Uma | - |
dc.contributor.author | Tsourti, Zoi | - |
dc.contributor.author | Michielin, Olivier | - |
dc.contributor.author | Pommeret, Fanny | - |
dc.contributor.author | Brunet, Joan | - |
dc.contributor.author | Vincenzi, Bruno | - |
dc.contributor.author | Tonini, Giuseppe | - |
dc.contributor.author | Patriarca, Andrea | - |
dc.contributor.author | Biello, Federica | - |
dc.contributor.author | Krengli, Marco | - |
dc.contributor.author | Tabernero Caturla, Josep | - |
dc.contributor.author | Pentheroudakis, George | - |
dc.contributor.author | Gennari, Alessandra | - |
dc.contributor.author | Peters, Solange | - |
dc.contributor.author | Romano, Emanuela | - |
dc.contributor.author | Pinato, David J. | - |
dc.date.accessioned | 2023-04-27T14:05:25Z | - |
dc.date.available | 2023-04-27T14:05:25Z | - |
dc.date.issued | 2022-11 | - |
dc.identifier.issn | 2051-1426 | - |
dc.identifier.uri | http://hdl.handle.net/2445/197296 | - |
dc.description.abstract | Background: As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer. Methods: In a joint analysis of ICI recipients from OnCovid (NCT04393974) and European Society for Medical Oncology (ESMO) CoCARE registries, we assessed severity and mortality from SARS-CoV-2 in vaccinated and unvaccinated patients with cancer and explored whether prior immune-related adverse events (irAEs) influenced outcome from COVID-19. Findings: The study population consisted of 240 patients diagnosed with COVID-19 between January 2020 and February 2022 exposed to ICI within 3 months prior to COVID-19 diagnosis, with a 30-day case fatality rate (CFR30) of 23.6% (95% CI 17.8 to 30.7%). Overall, 42 (17.5%) were fully vaccinated prior to COVID-19 and experienced decreased CFR30 (4.8% vs 28.1%, p=0.0009), hospitalization rate (27.5% vs 63.2%, p<0.0001), requirement of oxygen therapy (15.8% vs 41.5%, p=0.0030), COVID-19 complication rate (11.9% vs 34.6%, p=0.0040), with a reduced need for COVID-19-specific therapy (26.3% vs 57.9%, p=0.0004) compared with unvaccinated patients. Inverse probability of treatment weighting (IPTW)-fitted multivariable analysis, following a clustered-robust correction for the data source (OnCovid vs ESMO CoCARE), confirmed that vaccinated patients experienced a decreased risk of death at 30 days (adjusted OR, aOR 0.08, 95% CI 0.01 to 0.69).Overall, 38 patients (15.8%) experienced at least one irAE of any grade at any time prior to COVID-19, at a median time of 3.2 months (range 0.13-48.7) from COVID-19 diagnosis. IrAEs occurred independently of baseline characteristics except for primary tumor (p=0.0373) and were associated with a significantly decreased CFR30 (10.8% vs 26.0%, p=0.0462) additionally confirmed by the IPTW-fitted multivariable analysis (aOR 0.47, 95% CI 0.33 to 0.67). Patients who experienced irAEs also presented a higher median absolute lymphocyte count at COVID-19 (1.4 vs 0.8 109 cells/L, p=0.0098). Conclusion: Anti-SARS-CoV-2 vaccination reduces morbidity and mortality from COVID-19 in ICI recipients. History of irAEs might identify patients with pre-existing protection from COVID-19, warranting further investigation of adaptive immune determinants of protection from SARS-CoV-2. | - |
dc.format.extent | 20 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BMJ Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1136/jitc-2022-005732 | - |
dc.relation.ispartof | Journal for ImmunoTherapy of Cancer , 2022, vol. 10, num. 11, p. e005732 | - |
dc.relation.uri | https://doi.org/10.1136/jitc-2022-005732 | - |
dc.rights | cc-by (c) Cortellini, Alessio et al., 2022 | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | - |
dc.source | Articles publicats en revistes (Ciències Clíniques) | - |
dc.subject.classification | COVID-19 | - |
dc.subject.classification | SARS-CoV-2 | - |
dc.subject.classification | Citotoxicitat per mediació cel·lular | - |
dc.subject.classification | Immunitat cel·lular | - |
dc.subject.classification | Immunologia | - |
dc.subject.classification | Immunogenètica | - |
dc.subject.classification | Vacunes | - |
dc.subject.classification | Immunoteràpia | - |
dc.subject.classification | Malalts de càncer | - |
dc.subject.other | COVID-19 | - |
dc.subject.other | SARS-CoV-2 | - |
dc.subject.other | Cell-mediated cytotoxicity | - |
dc.subject.other | Cellular immunity | - |
dc.subject.other | Immunology | - |
dc.subject.other | Immunogenetics | - |
dc.subject.other | Vaccines | - |
dc.subject.other | Immunotheraphy | - |
dc.subject.other | Cancer patients | - |
dc.title | Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 728846 | - |
dc.date.updated | 2023-04-27T14:05:25Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 36450384 | - |
Appears in Collections: | Articles publicats en revistes (Ciències Clíniques) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
728846.pdf | 1.72 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License